Review yields mixed results for off-label antipsychotic use

09/28/2011 | HealthDay News

A meta-analysis published in the Journal of the American Medical Association shows that off-label use of atypical antipsychotics varies in benefit and risk. Researchers said Risperdal, Abilify and Zyprexa have a small but significant benefit for dementia patients. However, they found no evidence that atypical antipsychotics help those with an eating disorder or substance abuse. Furthermore, the drugs are associated with several risks, including stroke in the elderly and restless legs syndrome in younger patients.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC